The role of chemotherapy at the end of life: "when is enough, enough?".
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18544726.
- Also identified by DOI 10.1001/jama.299.22.2667 and PMC identifier 3099412.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients face difficult decisions about chemotherapy near the end of life. Such treatment might prolong survival or reduce symptoms but cause adverse effects, prevent the patient from engaging in meaningful life review and preparing for death, and preclude entry into hospice. Palliative care and oncology clinicians should be logical partners in caring for patients with serious cancers for which symptom control, medically appropriate goal setting, and communication are paramount, but some studies have shown limited cooperation. We illustrate how clinicians involved in palliative care and oncology can more effectively work together with the story of Mr L, a previously healthy 56-year-old man, who wanted to survive his lung cancer at all costs. He lived 14 months with 3 types of chemotherapy, received chemotherapy just 6 days before his death, and resisted entering hospice until his prognosis and options were explicitly communicated. Approaches to communication about prognosis and treatment options and questions that patients may want to ask are discussed.
Medical subject headings
- Antineoplastic Agents
- Interprofessional Relations
- Lung Neoplasms
- Medical Oncology
- Palliative Care
- Patient Acceptance of Health Care
- Physician-Patient Relations
- Terminally Ill